Article

 

HartungDanielPharmacyCostMulitpleSclerosis(Podcast).mp3 Public Deposited

Downloadable Content

Download audio
https://ir.library.oregonstate.edu/concern/articles/4b29b763q

Descriptions

Attribute NameValues
Creator
Abstract
  • Objective: To examine the pricing trajectories in the United States of disease-modifying therapies (DMT) for multiple sclerosis (MS) over the last 20 years and assess the influences on rising prices. Methods: We estimated the trend in annual drug costs for 9 DMTs using published drug pricing data from 1993 to 2013. We compared changes in DMT costs to general and prescription drug inflation during the same period. We also compared the cost trajectories for first-generation MS DMTs interferon (IFN)–β-1b, IFN-β-1a IM, and glatiramer acetate with contemporaneously approved biologic tumor necrosis factor (TNF) inhibitors. Results: First-generation DMTs, originally costing $8,000 to $11,000, now cost about $60,000 per year. Costs for these agents have increased annually at rates 5 to 7 times higher than prescription drug inflation. Newer DMTs commonly entered the market with a cost 25%–60% higher than existing DMTs. Significant increases in the cost trajectory of the first-generation DMTs occurred following the Food and Drug Administration approvals of IFN-β-1a SC (2002) and natalizumab (reintroduced 2006) and remained high following introduction of fingolimod (2010). Similar changes did not occur with TNF inhibitor biologics during these time intervals. DMT costs in the United States currently are 2 to 3 times higher than in other comparable countries. Conclusions: MS DMT costs have accelerated at rates well beyond inflation and substantially above rates observed for drugs in a similar biologic class. There is an urgent need for clinicians, payers, and manufacturers in the United States to confront the soaring costs of DMTs.
Rights Statement
Additional Information
  • description.provenance : Submitted by Patricia Black (patricia.black@oregonstate.edu) on 2015-12-01T19:57:49Z No. of bitstreams: 5 license_rdf: 1232 bytes, checksum: bb87e2fb4674c76d0d2e9ed07fbb9c86 (MD5) HartungDanielPharmacyCostMulitpleSclerosis.pdf: 895740 bytes, checksum: c9ead764f8d882269951495f84301c33 (MD5) HartungDanielPharmacyCostMulitpleSclerosis(Correction).pdf: 154701 bytes, checksum: 8a04a7ae7c3e587f98ccf843641801d5 (MD5) HartungDanielPharmacyCostMulitpleSclerosisSupplementaryAppendix.pdf: 116709 bytes, checksum: 38722a544d0e6dfa596c79a240a93fc3 (MD5) HartungDanielPharmacyCostMulitpleSclerosis(Podcast).mp3: 43491854 bytes, checksum: 2695e715ceb2455705990b89cca05b7d (MD5)
  • description.provenance : Approved for entry into archive by Patricia Black(patricia.black@oregonstate.edu) on 2015-12-01T19:58:24Z (GMT) No. of bitstreams: 5 license_rdf: 1232 bytes, checksum: bb87e2fb4674c76d0d2e9ed07fbb9c86 (MD5) HartungDanielPharmacyCostMulitpleSclerosis.pdf: 895740 bytes, checksum: c9ead764f8d882269951495f84301c33 (MD5) HartungDanielPharmacyCostMulitpleSclerosis(Correction).pdf: 154701 bytes, checksum: 8a04a7ae7c3e587f98ccf843641801d5 (MD5) HartungDanielPharmacyCostMulitpleSclerosisSupplementaryAppendix.pdf: 116709 bytes, checksum: 38722a544d0e6dfa596c79a240a93fc3 (MD5) HartungDanielPharmacyCostMulitpleSclerosis(Podcast).mp3: 43491854 bytes, checksum: 2695e715ceb2455705990b89cca05b7d (MD5)
  • description.provenance : Made available in DSpace on 2015-12-01T19:58:24Z (GMT). No. of bitstreams: 5 license_rdf: 1232 bytes, checksum: bb87e2fb4674c76d0d2e9ed07fbb9c86 (MD5) HartungDanielPharmacyCostMulitpleSclerosis.pdf: 895740 bytes, checksum: c9ead764f8d882269951495f84301c33 (MD5) HartungDanielPharmacyCostMulitpleSclerosis(Correction).pdf: 154701 bytes, checksum: 8a04a7ae7c3e587f98ccf843641801d5 (MD5) HartungDanielPharmacyCostMulitpleSclerosisSupplementaryAppendix.pdf: 116709 bytes, checksum: 38722a544d0e6dfa596c79a240a93fc3 (MD5) HartungDanielPharmacyCostMulitpleSclerosis(Podcast).mp3: 43491854 bytes, checksum: 2695e715ceb2455705990b89cca05b7d (MD5) Previous issue date: 2015-05-26

Relationships

Parents:

Items